Identifying Predictive Markers for Psoriasis Treatment Response

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to enhance psoriasis treatment by identifying genetic markers that predict how patients will respond to specific biologic therapies. Participants will receive two FDA-approved psoriasis medications over an 8-week period, during which their skin condition will be monitored, and biological samples will be collected for analysis. The goal is to develop a personalized treatment approach that minimizes the trial-and-error method currently used in psoriasis management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosed with plaque-type psoriasis defined by either:

  * A board-certified dermatologist, OR
  * Dermatology Nurse Practitioner, OR
  * Skin punch biopsy
* Insurance that includes an anti-p40 biologic (ustekinumab/.Stelara) and at least one anti-p19 biologic (guselkumab/Tremfya or risankizumab/Skyrizi)
* Must be naive to ustekinumab, guselkumab, and risankizumab.
* Involvement of body surface area (BSA) of at least 10% at screening and baseline visit.
* Able to give informed consent under IRB approval procedures

Exclusion Criteria:

* Pregnant, breastfeeding, or planning to get pregnant 8 weeks before, during, and 8 weeks after the study.
* Inability to provide informed consent
* Inability to secure ustekinumab and either gusekumab or risankizumab for use while on trial
* Use of tanning booths for at least 4 weeks prior to baseline visit
* Current or recent use of topical steroid, tar, phototherapy, Vitamin D, or retinoid therapy to target lesions for at least 2 weeks prior to baseline visit and for duration of trial
* Current or recent use of systemic or biologic therapy for at least 8 weeks prior to baseline visit
* Patients with psoriatic arthritis or other rheumatologic diseases (e.g., Crohn's disease).

Where it's running

• University Hospitals Cleveland Medical Center
  Cleveland, Ohio, United States Recruiting

Study contacts

• Principal investigator: Kevin Cooper, MD — University Hospitals Cleveland Medical Center
• Study coordinator: Amy Johnson, MD
• Email: Amy.Johnson@UHhospitals.org
• Phone: 216-286-7369

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Guselkumab after Ustekinumab in adults with moderate-to-severe psoriasis in routine care

  This study looks at how well guselkumab works for people with moderate-to-severe psoriasis after switching from ustekinumab in everyday clinical practice.

  Recruiting Janssen-Cilag Kft. · Budapest · NCT07746583

• Investigating how ustekinumab distributes in inflamed tissues for Crohn's disease and psoriasis

  This study is testing how well the drug ustekinumab works in people with Crohn's disease and psoriasis who haven't found relief from other treatments by looking at where the drug goes in their inflamed tissues.

  Recruiting Phase 1 University Medical Center Groningen · Groningen · NCT05725876

• HB0017 Injection safety and PK in low-weight adults at different injection sites

  This early-phase study tests a single subcutaneous HB0017 injection in healthy, low-weight adults and compares how the body processes the drug when injected at different sites.

  Recruiting Phase 1 Huabo Biopharm Co., Ltd. · Hangzhou, Zhejiang · NCT07920861

• MK-8644: first-in-human test in healthy people and people with psoriasis

  This early-phase study tests MK-8644 versus placebo in healthy volunteers and people with psoriasis to see if it is safe and tolerable.

  Recruiting Phase 1 Merck Sharp & Dohme LLC · Melbourne, Victoria · NCT07850310

• Is XJH05 Ointment Effective for Plaque Psoriasis?

  This study tests whether the XJH05 ointment can help people with plaque psoriasis compare to a calcipotriol ointment.

  Recruiting Xijing Hospital · Xi'an, Shaanxi · NCT07780929

• TQH3906 capsules vs warmer options in adults with moderate to severe plaque psoriasis

  This Phase 3 trial tests whether once-daily TQH3906 capsules can help adults with moderate to severe plaque psoriasis better than a placebo or the active drug deucravacitinib.

  Recruiting at 13 sites Phase 3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 44 other locations · NCT07724366

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.